Mr. Sangwoo Park is the founder and president of NKMAX, a leading Korean biotech company that specializes in the development and manufacture of antibodies and proteins. Through Mr. Park’s vision and leadership, NKMax is bringing its cutting-edge autologous and allogenic natural killer cell therapy to patients worldwide through NKGen Biotech. Prior to founding NKMAX, Mr. Park worked as a financial analyst at Samsung securities. Mr. Park earned his B.A. degree in economics from Korea University, Seoul Korea.